Purpose
This study was designed to determine whether biofeedback is more effective than diazepam or placebo in a randomized, controlled
trial for patients with pelvic floor dyssynergia-type constipation, and whether instrumented biofeedback is necessary for
successful training.
Methods
A total of 117 patients participated in a four-week run-in (education and medical management). The 84 who remained constipated
were randomized to biofeedback (n=30), diazepam (n=30), or placebo (n=24). All patients were trained to do pelvic floor muscle
exercises to correct pelvic floor dyssynergia during six biweekly one-hour sessions, but only biofeedback patients received
electromyography feedback. All other patients received pills one to two hours before attempting defecation. Diary data on
cathartic use, straining, incomplete bowel movements, Bristol stool scores, and compliance with homework were reviewed biweekly.
Results
Before treatment, the groups did not differ on demographic (average age, 50 years; 85 percent females), physiologic or psychologic
characteristics, severity of constipation, or expectation of benefit. Biofeedback was superior to diazepam by intention-to-treat
analysis (70 vs. 23 percent reported adequate relief of constipation 3 months after treatment, chi-squared=13.1, P<0.001), and also superior to placebo (38 percent successful, chi-squared=5.7, P=0.017). Biofeedback patients had significantly more unassisted bowel movements at follow-up compared with placebo (P=0.005), with a trend favoring biofeedback over diazepam (P=0.067). Biofeedback patients reduced pelvic floor electromyography during straining significantly more than diazepam patients
(P<0.001).
Conclusions
This investigation provides definitive support for the efficacy of biofeedback for pelvic floor dyssynergia and shows that
instrumented biofeedback is essential to successful treatment.
Key words Biofeedback - Constipation - Dyssynergia - Dyssynergic defecation - Electromyography
Support by NIDDK - Grant #R01DK57048, General Clinical Research Center, UNC at Chapel Hill, grant #RR00046, Sandhill® Scientific,
Incorporated, Jansen Pharmaceuticals, Milan Pharmaceuticals.
Presented at meeting of The American College of Gastroenterology, Honolulu, Hawaii, October 30 to November 2, 2005.